2017 American Transplant Congress
Kidney Transplantation in HCV+ Recipients in a New Era of Diagnostics and Therapeutics.
Duke University Medical Center, Durham, NC
BackgroundHepatitis-C infected persons (HCV+) evaluated for kidney transplantation receive rigorous staging of their liver disease, often including liver biopsy. Meanwhile, studies have shown that despite…2017 American Transplant Congress
The Safety and Efficacy of Directly-Acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-Analysis.
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Previous studies have reported that ribavirin-free regimens are effective for treating chronic hepatitis C virus genotype 1 infection. However, the efficacy and safety of ribavirin-free…2017 American Transplant Congress
Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney.
1UPENN, Philadelphia, PA; 2Yale, New Haven, CT
Background: New HCV drugs could reduce the risks of donor-derived HCV infection. However, it is unknown if HCV-negative (HCV-) ESRD patients would accept an HCV+…2017 American Transplant Congress
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).
Multi Transplant Organ Center, St Vincent Medical Center, Los Angeles, CA
Reports of efficacy of Direct Acting Antiviral drugs (DAA) > 90% in treatment of chronic HCV genotype 1, [GT1, 12 wk Sustained Viral Response (SVR12)]…2017 American Transplant Congress
Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission.
Background Less than 0.2 % of initially NAT(+) upon retesting are reported as NAT negative. However, there is a concern that these results could be…2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…2017 American Transplant Congress
Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.
Dermatology, Drexel, Philadelphia
Purpose: HIV and HCV are two immune dysregulatory processes that may exacerbate the risk of nonmelanoma skin cancer (NMSC) in organ transplant recipients (OTR), a…2017 American Transplant Congress
A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.
Background: HCV cirrhosis is the leading indication for liver transplantation in the U.S. The development of direct acting anti-viral agents (DAAs) has changed the approach…2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…2017 American Transplant Congress
Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents?
Background: Treatment with direct-acting antiviral agents (DAAs) in HCV patients is associated with high sustained virologic response (SVR) rates. It is hoped that cirrhosis regresses…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 28
- Next Page »